top of page
Composite picture of lung showing its structure superimposed with a DNA helix

MSCA Doctoral Network LifeLUNG

Omniscope

Beneficiary Partner

Photo of Omniscope premises at a modern science park building

Omniscope is an innovative Systems Diagnostics company providing sensitive solutions to read the adaptive immune system at high definition. The diverse and interdisciplinary team is built on two pillars: the company’s proprietary single-cell sequencing technologies and the AI-enabled computational capacity. osT and osB are the core unparalleled technologies that allow sequencing of T or B cells per sample at single-cell and ultra-high resolution, at least 100 times more than state-of-art methods. There is no single other platform that combines the functionality offered by osT/B: T/B cells at single-cell and ultra-high resolution; sensitive clonal counting; detection of minute numbers of tumor reactive/therapy related cells; providing full-length information about the V(D)J TCR/BCR region; the pairing of alpha and beta receptor chains for screening optimization; precise clonal tracking.

LifeLUNG logo

This project has received funding from the European Union’s Framework Programme for Research and Innovation, Horizon Europe under Grant Agreement No. 101227159 (HORIZON-MSCA-2024-DN-01)

  • Linkedin

Follow us on 

Funded by the European Union

Funded by the European Union. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or the Research Executive Agency. Neither the European Union nor the granting authority can be held responsible for them.

Project funded by Swiss Confederation

©2025 by LifeLUNG. Made with pride by Websters

bottom of page